Pathfinder Consortium

The Pathfinder Consortium is a national biodefense alliance launched in March 2026 by Lunai Bioworks (NASDAQ: LNAI) and its subsidiary BioSymetrics. The consortium is designed to accelerate the discovery and development of medical countermeasures against chemical warfare agents and emerging terrorism threats. By integrating academic toxicology, military research, and AI-driven phenotypic screening, the consortium aims to compress the traditional drug development timeline into a 36-month regulatory pathway. Its operational model utilizes high-throughput vertebrate screening in zebrafish and machine learning to identify therapeutic leads and repurpose existing FDA-approved drugs. The consortium targets large-scale U.S. federal procurement programs with potential contract values ranging from $400 million to $1.2 billion.